Preventive Vaccines Market

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the preventive vaccines market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to vaccines, as well as their classification based on the type of active ingredient. The chapter also includes an overview of the various expression systems that have been / are being used in the development and production of vaccines. Along with these, later sections highlight a discussion on the various routes of vaccine administration. It also features a brief overview of clinical development and approval processes for vaccines. The chapter ends with a discussion on the challenges and growth drivers that are likely to impact the evolution of the vaccines market in the comping years. 

Chapter 4 provides a detailed assessment of the current market landscape of over 200 preventive vaccines that are currently being evaluated in different stages of development. It features a comprehensive analysis of pipeline molecules based on a number of parameters, such as type of developer (industry, non-industry, industry / non-industry), phase of development (phase I, phase I/II, phase II, phase II/III, phase III and preregistration) of lead candidates, route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others), type of vaccine API (live, attenuated vaccine, recombinant vaccine, conjugate vaccine, inactivated vaccine, DNA vaccine, peptide vaccine, subunit vaccine, mRNA vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule and tablet), dosage (single dose, 2 doses, 3 doses, 4 doses, 5 doses and 6 doses), target disease indication and target patient population (children, adults and seniors).

Chapter 5 features an insightful company competitiveness analysis of preventive vaccine developers based in North America, Europe and Asia Pacific. The analysis presents a comparison of the companies within each geography on the basis of supplier strength (based on company size and its experience in this field) and pipeline strength (based on number of clinical-stage vaccine candidates, highest phase of development, number of compatible routes of administration, number of indication evaluated, number of APIs evaluated and target patient population).

Chapter 6 provides elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific. Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available). In addition to this, the profile includes information on the various clinical-stage vaccine candidates developed by the company. Further, we have provided the recent developments of the company and an informed future outlook.

Chapter 7 presents a detailed analysis of more than 1,400 completed, ongoing and planned clinical studies of preventive vaccines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, type of preventive vaccine (based on pathogen), target disease indication(s),  type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.

Chapter 8 provides an overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, ebola virus disease, HIV/AIDS, malaria and zika virus infection, including information on disease, its global burden, current treatment landscape and preventive vaccine research landscape. Further, we have provided the information on investments made and recent developments in the domain.

Chapter 9 presents an analysis of the investments made in this domain, during the period between 2015 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in developing preventive vaccines. 

Chapter 10 features a comprehensive market forecast, highlighting the future potential of this market till 2030 based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] route of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others), [B] type of vaccine (pneumococcal conjugate vaccine, human papilloma virus vaccine, influenza vaccine, rotavirus vaccine, varicella vaccine, DTP-HepB-Hib vaccine, meningococcal group A, C, Y and W-135 vaccine and Other), [C] type of API (live attenuated vaccine, inactivated vaccine, conjugate vaccine, subunit vaccine, toxoid vaccine and others), [D] target patient population (pediatric and adults) and [E] key geographical regions, covering North America (the US, Mexico and Canada), Europe (Spain, the UK, Italy, France, Germany and rest of Europe), Asia Pacific (India, China, Australia and rest of Asia Pacific), and rest of the world. 

Chapter 11 presents a case study on contract manufacturing landscape for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

Chapter 12 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 is a collection of interview transcripts of discussions held with key stakeholder(s) in this market. 

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Preventive Vaccines
3.2.1. Classification of Vaccines
3.2.1.1. Live, Attenuated Vaccines
3.2.1.2. Inactivated Vaccines
3.2.1.3. Subunit Vaccines
3.2.1.4. Toxoid Vaccines
3.2.1.5. DNA Vaccines

3.2.2. Key Components of a Vaccine Formulation
3.2.3. Production of Vaccines using Different Expression Systems
3.2.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.2.3.2. Mammalian Expression Systems
3.2.3.3. Avian Expression Systems
3.2.3.4. Plant Expression Systems
3.2.3.5. Bacterial Expression Systems
3.2.3.6. Yeast Expression Systems
3.2.3.7. Insect Expression System

3.2.4. Routes of Vaccine Administration
3.2.4.1. Intramuscular Route
3.2.4.2. Subcutaneous Route
3.2.4.3. Oral Route
3.2.4.4. Intranasal Route
3.2.4.5. Intradermal Route
3.2.4.6. Inhalation

3.2.5. Clinical Development and Approval of Vaccines
3.2.6. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Preventive Vaccines: Overall Market Landscape
4.2.1. Marketed Vaccines Landscape
4.2.2. Clinical-Stage Vaccines Landscape
4.2.2.1. Analysis by Type of Developer
4.2.2.2. Analysis by Phase of Development
4.2.2.3. Analysis by Route of Administration
4.2.2.4. Analysis by Type of Vaccine API
4.2.2.5. Analysis by Dosage Form
4.2.2.6. Analysis by Dosage
4.2.2.7. Analysis by Target Disease Indication
4.2.2.8. Analysis by Target Patient Population
4.2.2.9. Key Industry Players: Analysis by Number of Vaccines in Clinical Development
4.2.2.10. Key Non-Industry Players: Analysis by Number of Vaccines in Clinical Development

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. Competitiveness Analysis: Preventive Vaccine Developers
5.4.1. Preventive Vaccine Developers based in North America
5.4.2. Preventive Vaccine Developers based in Europe
5.4.3. Preventive Vaccine Developers based in Asia Pacific

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Bio Farma
6.2.1. Company Overview
6.2.2. Preventive Vaccines Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Emergent BioSolutions
6.3.1. Company Overview
6.3.2. Preventive Vaccines Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. GC Pharma
6.4.1. Company Overview
6.4.2. Preventive Vaccines Portfolio
6.4.3. Recent Developments and Future Outlook

6.5. GlaxoSmithKline
6.5.1. Company Overview
6.5.2. Preventive Vaccines Portfolio
6.5.3. Recent Developments and Future Outlook

6.6. Janssen
6.6.1. Company Overview
6.6.2. Preventive Vaccines Portfolio
6.6.3. Recent Developments and Future Outlook

6.7. Merck
6.7.1. Company Overview
6.7.2. Preventive Vaccines Portfolio
6.7.3. Recent Developments and Future Outlook

6.8. Novavax
6.8.1. Company Overview
6.8.2. Preventive Vaccines Portfolio
6.8.3. Recent Developments and Future Outlook

6.9. Pfizer
6.9.1. Company Overview
6.9.2. Preventive Vaccines Portfolio
6.9.3. Recent Developments and Future Outlook

6.10. Sanofi Pasteur
6.10.1. Company Overview
6.10.2. Preventive Vaccines Portfolio
6.10.3. Recent Developments and Future Outlook

6.11. Valneva
6.11.1. Company Overview
6.11.2. Preventive Vaccines Portfolio
6.11.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Preventive Vaccines: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Enrolled Patient Population and Trial Registration Year
7.3.3. Analysis by Trial Phase
7.3.4. Analysis by Trial Recruitment Status
7.3.5. Analysis by Study Design
7.3.6. Analysis by Trial Focus Area
7.3.7. Analysis by Type of Preventive Vaccine (based on Pathogen)
7.3.8. Analysis by Target Disease Indication
7.3.9. Analysis by Type of Sponsor / Collaborator
7.3.10. Leading Industry Players: Analysis by Number of Registered Trials
7.3.11. Geographical Analysis by Number of Registered Trials
7.3.12. Geographical Analysis by Enrolled Patient Population
7.3.13. Geographical Analysis by Trial Recruitment Status

8. ONGOING VACCINE DEVELOPMENT INITIATIVES FOR COMPLEX CONDITIONS
8.1. Chapter Overview
8.2. Coronavirus Disease (COVID-19)
8.2.1. Disease Overview
8.2.2. Global Burden of COVID-19
8.2.3. Current Treatment Landscape
8.2.4. Preventive Vaccines for COVID-19
8.2.4.1. Historical Background of COVID-19 Vaccine Research
8.2.4.2. COVID-19 and Affiliated Research Landscape
8.2.5. Funding Instances
8.2.6. Recent Developments

8.3. Ebola Virus Disease (EVD)
8.3.1. Disease Overview
8.3.2. Global Burden of EVD
8.3.3. Current Treatment Landscape
8.3.4. Preventive Vaccines for EVD
8.3.4.1. Historical Background of Ebola Virus Vaccine Research
8.3.4.2. Anti-Ebola Virus Vaccines and Affiliated Research Landscape
8.3.5. Funding Instances
8.3.6. Recent Developments

8.4. HIV/AIDS
8.4.1. Disease Overview
8.4.2. Global Burden of HIV/AIDS
8.4.3. Current Treatment Landscape
8.4.4. Preventive Vaccines for HIV/AIDS
8.4.4.1. Historical Background of HIV/AIDS Vaccine Research
8.4.4.2. Anti-HIV Vaccines and Affiliated Research Landscape
8.4.5. Funding Instances
8.4.6. Recent Developments

8.5. Malaria
8.5.1. Disease Overview
8.5.2. Global Burden of Malaria
8.5.3. Current Treatment Landscape
8.5.4. Preventive Vaccines for Malaria
8.5.4.1. Historical Background of Malaria Vaccine Research
8.5.4.2. Anti-Malaria Vaccines and Affiliated Research Landscape
8.5.5. Funding Instances
8.5.6. Recent Developments

8.6. Zika Virus Infection
8.6.1. Disease Overview
8.6.2. Global Burden of Zika Virus Infection
8.6.3. Current Treatment Landscape
8.6.4. Preventive Vaccines for Zika Virus Infection
8.6.4.1. Historical Background of Zika Virus Vaccine Research
8.6.4.2. Anti-Zika Virus Vaccines and Affiliated Research Landscape
8.6.5. Funding Instances
8.6.6. Recent Developments

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Preventive Vaccines: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Amount Invested across Different Types of Vaccine API
9.3.5. Analysis by Focus Area
9.3.6. Analysis by Amount Invested by Different Type of Investors
9.3.7. Most Active Players: Analysis by Number of Funding Instances
9.3.8. Most Active Investors: Analysis by Number of Funding Instances
9.3.9. Analysis by Geography
9.3.9.1. Continent-wise Analysis
9.3.9.2. Country-wise Analysis

10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall Preventive Vaccines Market, 2020-2030
10.3.1. Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration
10.3.2. Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine
10.3.3. Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API
10.3.4. Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population
10.3.5. Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions
10.3.5.1. Preventive Vaccines Market in North America, 2020-2030
10.3.5.1.1. Preventive Vaccines Market in the US, 2020-2030
10.3.5.1.2. Preventive Vaccines Market in Mexico, 2020-2030
10.3.5.1.2. Preventive Vaccines Market in Canada, 2020-2030

10.3.5.2. Preventive Vaccines Market in Europe, 2020-2030
10.3.5.2.1. Preventive Vaccines Market in Spain, 2020-2030
10.3.5.2.2. Preventive Vaccines Market in the UK, 2020-2030
10.3.5.2.3. Preventive Vaccines Market in Italy, 2020-2030
10.3.5.2.4. Preventive Vaccines Market in France, 2020-2030
10.3.5.2.5. Preventive Vaccines Market in Germany, 2020-2030
10.3.5.2.6. Preventive Vaccines Market in Rest of Europe, 2020-2030

10.3.5.3. Preventive Vaccines Market in Asia Pacific, 2020-2030
10.3.5.3.1. Preventive Vaccines Market in India, 2020-2030
10.3.5.3.2. Preventive Vaccines Market in China, 2020-2030
10.3.5.3.3. Preventive Vaccines Market in Australia, 2020-2030
10.3.5.3.4. Preventive Vaccines Market in Rest of Asia Pacific, 2020-2030

10.3.5.4. Preventive Vaccines Market in Rest of the World, 2020-2030
 
11. CASE-IN-POINT: CONTRACT MANUFACTURING OF VACCINES
11.1. Chapter Overview
11.2. Vaccine Contract Manufacturing
11.2.1. Addressing an Unmet Need
11.2.2. Commonly Outsourced Operations
11.2.3. Selecting a CMO Partner
11.2.4. Advantages of Outsourcing Manufacturing Services
11.2.5. Associated Risks and Challenges

11.3. Vaccine Contract Manufacturing: Overall Market Landscape
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Scale of Operation
11.3.4. Analysis by Location of Headquarters
11.3.5. Analysis by Location of Manufacturing Facilities
11.3.6. Analysis by Type of Service(s) Offered
11.3.7. Analysis by Expression System Used
11.3.8. Analysis by Type of Vaccine Manufactured
11.3.9. Analysis by Type of Vaccine Manufactured and Location of Headquarters

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview

13.2. Alopexx
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Daniel R. Vlock, Chief Executive Officer

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Difference Between Vaccines and Small Molecules
Figure 3.2 Classification of Vaccines
Figure 3.3 Routes for Vaccine Administration
Figure 4.1 Clinical-Stage Preventive Vaccines: Distribution by Type of Developer
Figure 4.2 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
Figure 4.3 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
Figure 4.4 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
Figure 4.5 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
Figure 4.6 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
Figure 4.7 Clinical-Stage Preventive Vaccines: Distribution by Dosage
Figure 4.8 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
Figure 4.9 Clinical-Stage Preventive Vaccines: Distribution by Target Patient Population
Figure 4.10 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
Figure 4.11 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
Figure 5.1 Company Competitiveness Analysis: Preventive Vaccine Developers based in North America
Figure 5.2 Company Competitiveness Analysis: Preventive Vaccine Developers based in Europe
Figure 5.3 Company Competitiveness Analysis: Preventive Vaccine Developers based in Asia Pacific
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2020
Figure 7.3 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Pre-2010-2020
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 7.6 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 7.7 Clinical Trial Analysis: Distribution by Study Design
Figure 7.8 Clinical Trial Analysis: Distribution by Trial Focus Area
Figure 7.9 Clinical Trial Analysis: Distribution by Type of Preventive Vaccine (based on Pathogen)
Figure 7.10 Clinical Trial Analysis: Cumulative Year-wise Trend by Type of Preventive Vaccines
Figure 7.11 Clinical Trial Analysis: Distribution by Target Disease Indication
Figure 7.12 Clinical Trial Analysis: Distribution by Patient Enrollment and Target Disease Indication
Figure 7.13 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.14 Leading Industry Players: Distribution by Number of Registered Trials
Figure 7.15 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 7.16 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.17 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Figure 8.1 Historical Timeline of COVID-19 Vaccine Development
Figure 8.2 Historical Timeline of Anti-Ebola Virus Vaccine Development
Figure 8.3 Historical Timeline of Anti-HIV Vaccine Development
Figure 8.4 Historical Timeline of Anti-Malaria Vaccine Development
Figure 8.5 Historical Timeline of Anti-Zika Virus Vaccine Development
Figure 9.1 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2015-Q1 2020
Figure 9.2 Funding and Investment Analysis: Cumulative Amount Invested, 2015-Q1 2020 (USD Million)
Figure 9.3 Funding and Investment Analysis: Distribution by Type of Funding, 2015-Q1 2020
Figure 9.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2015-Q1 2020 (USD Million)
Figure 9.5 Funding and Investment Analysis: Distribution of Amount Invested by Type of Vaccine API
Figure 9.6 Funding and Investment Analysis: Distribution of Amount Invested and Focus Area
Figure 9.7 Funding and Investment Analysis: Distribution of Amount Invested by Different Type of Investors
Figure 9.8 Most Active Players: Distribution by Number of Funding Instances
Figure 9.9 Most Active Investors: Distribution by Number of Funding Instances
Figure 9.10 Funding and Investment Analysis: Regional Distribution by Number of Funding Instances and Amount Raised (USD Million)
Figure 9.11 Funding and Investment Analysis: Country-wise Distribution by Total Amount Invested (USD Million)
Figure 10.1 Overall Preventive Vaccines Market, 2020-2030 (USD Billion)
Figure 10.2 Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration (USD Billion)
Figure 10.3 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine (USD Billion)
Figure 10.4 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API (USD Billion)
Figure 10.5 Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population (USD Billion)
Figure 10.6 Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions (USD Billion)
Figure 10.7 Preventive Vaccines Market in North America, 2020-2030 (USD Billion)
Figure 10.8 Preventive Vaccines Market in the US, 2020-2030 (USD Billion)
Figure 10.9 Preventive Vaccines Market in Mexico, 2020-2030 (USD Billion)
Figure 10.10 Preventive Vaccines Market in Canada, 2020-2030 (USD Billion)
Figure 10.11 Preventive Vaccines Market in Europe, 2020-2030 (USD Billion)
Figure 10.12 Preventive Vaccines Market in Spain, 2020-2030 (USD Billion)
Figure 10.13 Preventive Vaccines Market in the UK, 2020-2030 (USD Billion)
Figure 10.14 Preventive Vaccines Market in Italy, 2020-2030 (USD Billion)
Figure 10.15 Preventive Vaccines Market in France, 2020-2030 (USD Billion)
Figure 10.16 Preventive Vaccines Market in Germany, 2020-2030 (USD Billion)
Figure 10.17 Preventive Vaccines Market in Rest of Europe, 2020-2030 (USD Billion)
Figure 10.18 Preventive Vaccines Market in Asia Pacific, 2020-2030 (USD Billion)
Figure 10.19 Preventive Vaccines Market in India, 2020-2030 (USD Billion)
Figure 10.20 Preventive Vaccines Market in China, 2020-2030 (USD Billion)
Figure 10.21 Preventive Vaccines Market in Australia, 2020-2030 (USD Billion)
Figure 10.22 Preventive Vaccines Market in Rest of Asia Pacific, 2020-2030 (USD Billion)
Figure 10.23 Preventive Vaccines Market in Rest of the World, 2020-2030 (USD Billion)
Figure 11.1 Type of Third-Party Service Providers in the Pharmaceutical Industry
Figure 11.2 Commonly Outsourced Vaccine Development Operations
Figure 11.3 Key Factors to Consider while Selecting a CMO Partner
Figure 11.4 Risks and Challenges Associated with Contract Manufacturing
Figure 11.5 Vaccine CMOs: Distribution by Year of Establishment
Figure 11.6 Vaccine CMOs: Distribution by Company Size
Figure 11.7 Vaccine CMOs: Distribution by Scale of Operation
Figure 11.8 Vaccine CMOs: Distribution by Location of Headquarters (Region and Country-wise)
Figure 11.9 Vaccine CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
Figure 11.10 Vaccine CMOs: Distribution by Type of Services Offered
Figure 11.11 Vaccine CMOs: Distribution by Expression System Used
Figure 11.12 Vaccine CMOs: Distribution by Type of Vaccine Manufactured
Figure 11.13 Vaccine CMOs: Distribution by Type of Vaccine Manufactured and Location of Headquarters

List Of Tables

Table 3.1 Classification of Vaccines
Table 3.2 Live, Attenuated Vaccines: Commonly Reported Adverse Events
Table 3.3 Inactivated Vaccines: Commonly Reported Adverse Events
Table 3.4 Subunit Vaccines: Commonly Reported Adverse Events
Table 3.5 Toxoid Vaccines: Commonly Reported Adverse Events
Table 3.6 Vaccine Excipients and their Functions
Table 3.7 Routes of Administration and Type of Delivery Devices for Vaccine Administration
Table 3.8 Common Pediatric Vaccines and their Routes of Administration
Table 4.1 List of Marketed Preventive Vaccines
Table 4.2 List of Clinical-Stage Preventive Vaccines
Table 6.1 Preventive Vaccine Developers: List of Companies Profiled
Table 6.2 Bio Farma: Company Overview
Table 6.3 Bio Farma: Preventive Vaccine Pipeline
Table 6.4 Bio Farma: Recent Developments and Future Outlook
Table 6.5 Emergent BioSolutions: Company Overview
Table 6.6 Emergent BioSolutions: Preventive Vaccine Pipeline
Table 6.7 Emergent BioSolutions: Recent Developments and Future Outlook
Table 6.8 GC Pharma: Company Overview
Table 6.9 GC Pharma: Preventive Vaccine Pipeline
Table 6.10 GC Pharma: Recent Developments and Future Outlook
Table 6.11 GlaxoSmithKline: Company Overview
Table 6.12 GlaxoSmithKline: Preventive Vaccine Pipeline
Table 6.13 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.14 Janssen: Company Overview
Table 6.15 Janssen: Preventive Vaccine Pipeline
Table 6.16 Janssen: Recent Developments and Future Outlook
Table 6.17 Merck: Company Overview
Table 6.18 Merck: Preventive Vaccine Pipeline
Table 6.19 Merck: Recent Developments and Future Outlook
Table 6.20 Novavax: Company Overview
Table 6.21 Novavax: Preventive Vaccine Pipeline
Table 6.22 Novavax: Recent Developments and Future Outlook
Table 6.23 Pfizer: Company Overview
Table 6.24 Pfizer: Preventive Vaccine Pipeline
Table 6.25 Pfizer: Recent Developments and Future Outlook
Table 6.26 Sanofi Pasteur: Company Overview
Table 6.27 Sanofi Pasteur: Preventive Vaccine Pipeline
Table 6.28 Sanofi Pasteur: Recent Developments and Future Outlook
Table 6.29 Valneva: Company Overview
Table 6.30 Valneva: Preventive Vaccine Pipeline
Table 6.31 Valneva: Recent Developments and Future Outlook
Table 8.1 Preventive Vaccines under Investigation for COVID-19
Table 8.2 COVID-19 Vaccines: Funding Instances
Table 8.3 Ebola Virus Disease: List of Marketed Therapeutics
Table 8.4 Preventive Vaccines under Investigation for Ebola Virus Disease
Table 8.5 Anti-Ebola Virus Vaccines: Funding Instances
Table 8.6 HIV/AIDS: List of Marketed Therapeutics
Table 8.7 Preventive Vaccines under Investigation for HIV/AIDS
Table 8.8 Anti-HIV Vaccines: Funding Instances
Table 8.9 Malaria: List of Marketed Therapeutics
Table 8.10 Preventive Vaccines under Investigation for Malaria
Table 8.11 Anti-Malaria Vaccines: Funding Instances
Table 8.12 Preventive Vaccines under Investigation for Zika Virus Infection
Table 8.13 Anti-Zika Virus Vaccines: Funding Instances
Table 9.1 Preventive Vaccines: List of Funding and Investments, till Q1 2020
Table 11.1 Vaccine Contract Manufacturers: List of Service Providers
Table 11.2 Vaccine CMOs: Information on Type of Services Offered
Table 11.3 Vaccine CMOs: Information on Scale of Operation
Table 11.4 Vaccine CMOs: Information on Expression System Used
Table 11.5 Vaccine CMOs: Information on Type of Vaccines Manufactured
Table 11.6 List of Ad hoc Vaccine Manufacturers
Table 12.1 Preventive Vaccines Market: Summary of the Report
Table 14.1 Clinical-Stage Preventive Vaccines: Distribution by Type of Developer
Table 14.2 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
Table 14.3 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
Table 14.4 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
Table 14.5 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
Table 14.6 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
Table 14.7 Clinical-Stage Preventive Vaccines: Distribution by Dosage
Table 14.8 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
Table 14.9 Clinical-Stage Preventive Vaccines: Distribution by Target Patient Population
Table 14.10 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
Table 14.11 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
Table 14.12 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2020
Table 14.13 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Pre-2010-2020
Table 14.14 Clinical Trial Analysis: Distribution by Trial Phase
Table 14.15 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 14.16 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 14.17 Clinical Trial Analysis: Distribution by Study Design
Table 14.18 Clinical Trial Analysis: Distribution by Trial Focus Area
Table 14.19 Clinical Trial Analysis: Distribution by Type of Preventive Vaccine (based on Pathogen)
Table 14.20 Clinical Trial Analysis: Cumulative Year-wise Trend by Type of Preventive Vaccines
Table 14.21 Clinical Trial Analysis: Distribution by Target Disease Indication
Table 14.22 Clinical Trial Analysis: Distribution by Patient Enrollment and Target Disease Indication
Table 14.23 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 14.24 Leading Industry Players: Distribution by Number of Registered Trials
Table 14.25 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2015-Q1 2020
Table 14.26 Funding and Investment Analysis: Cumulative Amount Invested, 2015-Q1 2020 (USD Million)
Table 14.27 Funding and Investment Analysis: Distribution by Type of Funding, 2015-Q1 2020
Table 14.28 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2015-Q1 2020 (USD Million)
Table 14.29 Funding and Investment Analysis: Distribution of Amount Invested by Type of Vaccine API
Table 14.30 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area
Table 14.31 Funding and Investment Analysis: Distribution of Amount Invested by Different Type of Investors
Table 14.32 Most Active Players: Distribution by Number of Funding Instances
Table 14.33 Most Active Investors: Distribution by Number of Funding Instances
Table 14.34 Funding and Investment Analysis: Regional Distribution by Number of Funding Instances and Amount Raised (USD Million)
Table 14.35 Funding and Investment Analysis: Country-wise Distribution by Total Amount Invested (USD Million)
Table 14.36 Overall Preventive Vaccines Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.37 Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration (USD Billion)
Table 14.38 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine (USD Billion)
Table 14.39 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API (USD Billion)
Table 14.40 Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population (USD Billion)
Table 14.41 Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions (USD Billion)
Table 14.42 Preventive Vaccines Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.43 Preventive Vaccines Market in the US, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.44 Preventive Vaccines Market in Mexico, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.45 Preventive Vaccines Market in Canada, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.46 Preventive Vaccines Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.47 Preventive Vaccines Market in Spain, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.48 Preventive Vaccines Market in the UK, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.49 Preventive Vaccines Market in Italy, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.50 Preventive Vaccines Market in France, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.51 Preventive Vaccines Market in Germany, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.52 Preventive Vaccines Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.53 Preventive Vaccines Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.54 Preventive Vaccines Market in India, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.55 Preventive Vaccines Market in China, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.56 Preventive Vaccines Market in Australia, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.57 Preventive Vaccines Market in Rest of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.58 Preventive Vaccines Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.59 Vaccine CMOs: Distribution by Year of Establishment
Table 14.60 Vaccine CMOs: Distribution by Company Size
Table 14.61 Vaccine CMOs: Distribution by Scale of Operation
Table 14.62 Vaccine CMOs: Distribution by Location of Headquarters (Region and Country-wise)
Table 14.63 Vaccine CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
Table 14.64 Vaccine CMOs: Distribution by Type of Services Offered
Table 14.65 Vaccine CMOs: Distribution by Expression System Used
Table 14.66 Vaccine CMOs: Distribution by Type of Vaccines Manufactured
Table 14.67 Vaccine CMOs: Region-wise Distribution by Type of Vaccine Manufactured

Listed Companies

The following companies and organizations have been mentioned in the report.

1. 3P Biopharmaceuticals
2. Abbott Biologicals
3. AbbVie Contract Manufacturing
4. Aberdeen Proving Ground
5. ABL
6. Abu Dhabi Investment Authority
7. Abzena
8. Adimmune 
9. Adjuvant Capital
10. Advagene Biopharma
11. Affinivax
12. AJ Biologics
13. AJ Vaccines
14. Ajinomoto Bio-Pharma Services
15. Alexandria Venture Investments
16. Alopexx Vaccine
17. Altimmune
18. AmbioPharm
19. AMRI
20. Anaxago
21. Angels High Tech Investments
22. Anhui Zhifei Longcom Biologic Pharmacy
23. ARCH Venture Partners
24. ArrowMark Partners
25. Astellas Pharma
26. Atlantic Methanol Production Company
27. Auro Vaccines
28. Avid Bioservices
29. AVIR Green Hills Biotechnology
30. aws Gründerfonds
31. Barr Laboratories
32. Batavia Biosciences
33. Bavarian Nordic
34. Baxter BioPharma Solutions
35. Baylor College of Medicine
36. BB Biotech
37. Beijing Center for Disease Control and Prevention
38. Beijing Institute of Biological Products
39. Beijing Minhai Biotechnology
40. Beijing Zhifei Lvzhu Biopharmaceutical
41. Bharat Biotech
42. Bharat Serums and Vaccine
43. Bill & Melinda Gates Foundation
44. Bilthoven Biologicals
45. BINEX
46. Bio Elpida
47. Bio Farma
48. BioCell
49. BioConnections
50. Biofabri
51. Biological E.
52. Bio-Manguinhos
53. BioMARC
54. Biomay
55. Biomedical Advanced Research and Development Authority
56. BioMedPartners
57. BiondVax Pharmaceuticals
58. BioReliance
59. BioTechLogic
60. BioTechnique
61. BlueWillow Biologics
62. Boehringer Ingelheim BioXcellence
63. Boehringer Ingelheim Venture Fund
64. Boryung Pharmaceutical
65. Brammer Bio
66. Bryllan
67. Bul Bio-National Center of Infectious and Parasitic Diseases
68. Burrard Pharmaceuticals
69. Cadila Healthcare
70. CanSino Biologics
71. CARBOGEN AMCIS
72. CARB-X
73. Catalent
74. Center for Genetic Engineering and Biotechnology
75. Century Pharmaceuticals
76. CEPI
77. Cerberus Capital Management
78. CEVEC Pharmaceuticals
79. Charles River Laboratories
80. Chengdu Institute of Biological Products 
81. Chiron Behring Vaccines
82. Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences
83. CJ HealthCare
84. Cobra Biologics
85. Codagenix
86. Consort Medical
87. CRG
88. CSL
89. CureVac
90. Curevo
91. Cytovance Biologics
92. Dalton Pharma Services
93. Danish Government
94. Danish Innovation Foundation
95. Dartmouth-Hitchcock Medical Center
96. Deerfield Management
97. Department of the Army
98. Division of AIDS
99. Duke Human Vaccine Institute
100. Dynavax Technologies
101. EDBI
102. EirGenix
103. Emergent BioSolutions
104. Emergent Product Development Gaithersburg
105. Emergex Vaccines
106. Ethiopian Government 
107. EuBiologics
108. Euclidean Capital
109. Eurofins Amatsigroup
110. Eurogentec
111. EDCTP
112. European Investment Bank
113. European Union
114. Eveliqure Biotechnologies
115. Farallon Capital
116. Federal State Budgetary Scientific Institution
117. FF DSF VI
118. Fidelity Investments
119. Fiocruz
120. FluGen
121. Forbion
122. Fort Detrick
123. Fortune Capital
124. FUJIFILM Diosynth Biotechnologies
125. FundRx
126. Future Industry Investment Fund
127. Gamaleya Research Institute of Epidemiology and Microbiology
128. GC Cell
129. GC Pharma
130. GeneMatrix
131. GeneOne Life Science
132. GenIbet Biopharmaceuticals
133. Georgia Institute of Technology
134. Gilead
135. GlaxoSmithKline
136. Global Health Investment Fund
137. Goldstone Investment
138. Gopher Asset Management
139. Government of the Republic of Equatorial Guinea
140. Government of Norway
141. GPO-MBP
142. GreenPak Biotech
143. GreenSignal Bio Pharma
144. GTP Technology
145. GV
146. Hadean Ventures
147. Haffkine Bio-Pharmaceutical
148. HALIX
149. Hawaii Biotech
150. HBM Partners
151. Health Biotech
152. HealthCap
153. Hillhouse Capital
154. Hong Kong Institute of Biotechnology
155. HOOKIPA Pharma
156. Hualan Biological Bacterin
157. Icahn School of Medicine at Mount Sinai
158. IDT Biologika
159. ILiAD Biotechnologies
160. Il-Yang Pharmaceutical
161. Immunobiological Technology Institute (BioManguinhos)
162. Imperial College London
163. Indian Immunologicals
164. Infectious Disease Research Institute
165. Innovate UK
166. Inovio Pharmaceuticals
167. Institut Pasteur de Dakar
168. Institute for Biomedical Science
169. Institute of Vaccines and Medical Biologicals
170. Instituto Nacional de Saúde
171. Intas
172. Integrity Bio
173. International AIDS Vaccine Initiative
174. International Centre for Diarrhoeal Disease Research, Bangladesh
175. International Vaccine Institute
176. Invus
177. Israel Innovation Authority
178. Israel Investment Center
179. Jack Ma Foundation
180. Janssen
181. Japan Bank for International Cooperation
182. Japan BCG Laboratory
183. JEMS Venture Capital
184. Jiangsu Provincial Center for Disease Control and Prevention
185. JN-International Medical
186. Johnson & Johnson Innovation
187. Joint Program Executive Office for Chemical and Biological Defense
188. JSR
189. Jubilant HollisterStier
190. Julius Baer
191. Kemwell Biopharma
192. King Abdullah International Medical Research Center
193. Knox
194. Korea Investment Partners
195. LF Investment
196. LG Chem
197. Lilly Asia Ventures
198. LimmaTech Biologics
199. Line Moon Ventures
200. Liontrust
201. Lonza
202. LuinaBio
203. Mahidol University
204. Marathon Oil Corporation
205. Massachusetts General Hospital
206. MassBiologics
207. MCM Vaccine
208. Ministry of Health of the Russian Federation
209. Medicago
210. Medical Countermeasure Systems–Joint Vaccine Acquisition Program
211. Medigen Vaccine Biologics
212. MedImmune
213. Meissa Vaccines
214. Merck
215. Meridian Life Science
216. MIKROGEN 
217. MinervaX
218. Ministry of Economic Affairs
219. Ministry of Foreign Affairs (Netherlands)
220. Moderna
221. Morningside Ventures
222. MRC/UVRI Uganda Research Unit on AIDS
223. MSD Wellcome Trust Hilleman Laboratories
224. Mymetics
225. Natick Contracting Division
226. National Authority for Technological Innovation
227. National Institute of Allergy and Infectious Diseases
228. National Institutes of Health
229. National Vaccine & Serum Institute
230. Network-1 Technologies
231. Nitto Avecia Pharma Services
232. Noble Energy
233. North Coast Technology Investors
234. Noshaq
235. Nova Immunotherapeutics
236. Novartis
237. Novartis Venture Fund
238. Novasep
239. Novavax
240. Novo Holdings
241. Novo Seeds
242. NPO Petrovax Pharm
243. Omnes Capital
244. OPKO Health
245. OrbiMed
246. Organon Teknika
247. Osivax
248. Oxford Sciences Innovation
249. Panacea Biotec
250. PATH
251. Perceptive Advisors
252. Pfizer
253. Pfizer CentreOne
254. Pictet
255. Pierre Fabre
256. Piramal Pharma Solutions
257. PnuVax
258. Polymun Scientific
259. Porton Biopharma
260. Premas Biotech
261. ProBioGen
262. Profectus BioSciences
263. Protein Sciences
264. PX’Therapeutics
265. Qiming Venture Partners
266. Redmile Group
267. Redmont Capital
268. Reliance Life Sciences
269. Research Foundation for Microbial Diseases, Osaka University
270. Richter-Helm Biologics
271. Rommelag CMO
272. RTW Investments
273. Russian Academy of Sciences
274. Sabin Vaccine Institute
275. Samsara BioCapital
276. Sanaria
277. Sanofi Pasteur
278. Scandinavian Biopharma
279. Scripps Research Institute
280. SDS Capital Partners
281. Seedlings Life Science Ventures
282. SEEK
283. Seqirus
284. Sequoia
285. Sequoia China
286. Serum Institute of India
287. Shanghai Bovax Biotechnology
288. Shantha Biotechnics
289. Sinovac Biotech
290. Sirona Capital
291. SK Bioscience
292. Sofinnova Partners
293. State of Wisconsin Investment Board
294. Sunstone Capital
295. Sunstone Life Science Ventures
296. Swissfillon
297. Syngene
298. Takeda
299. Takeda Ventures
300. Teva Pharmaceuticals
301. Texas Biomedical Research Institute
302. The Peter Doherty Institute for Infection and Immunity 
303. The Wistar Institute
304. Themis Bioscience
305. Thermo Fisher Scientific
306. Topspin Partners
307. Truffle Capital
308. UK Government
309. UK Research and Innovation
310. Univercells
311. University Health Network
312. University Medical Center Hamburg-Eppendorf
313. University of Amsterdam
314. University of Antwerp
315. University of California
316. University of Georgia
317. University of Maryland
318. University of Michigan
319. University of Minnesota
320. University of Oxford
321. University of Washington
322. US Agency for International Development
323. US Army Contracting Command
324. US Army Medical Research and Materiel Command
325. US Centers for Disease Control and Prevention
326. US Defense Advanced Research Projects Agency
327. US Defense Threat Reduction Agency
328. US Department of Agriculture
329. US Department of Defense
330. Vaccitech
331. Valneva
332. Vaxart
333. Vaxine
334. VaxNewMo
335. Vaxxilon
336. VBI Vaccines
337. Ventech
338. Venture Investors
339. Vetter Pharma
340. VGXI
341. Vibalogics
342. Vickers Venture Partners
343. Viking Global Investors
344. Wacker Biotech
345. Waisman Biomanufacturing
346. Wallace Pharmaceuticals
347. Wellington Partners Life Sciences
348. Wisconsin Alumni Research Foundation
349. WuXi Biologics
350. Wuxi Griffin
351. Wyeth Pharmaceuticals
352. Xiamen University
353. X-Vax Technology

Source 1: www.ncbi.nlm.nih.gov/pmc/articles/PMC6468175/
Source 2: www.worldbank.org/en/topic/infectiousdiseases